<p>Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint expressed on the surface of T cells. We conducted a comprehensive molecular characterization and clinical analysis of LAG3 expression in gliomas. Across the CGGA and TCGA glioma datasets, we observed that LAG3 expression increased with higher glioma grade. Further investigation into the molecular subtypes revealed that LAG3 exhibited the highest expression in the Mesenchymal subtype, similar to other immune checkpoints. CIBERSORT analysis showed a significant positive correlation between LAG3 expression and macrophages, suggesting LAG3’s involvement in shaping the immune microenvironment. Single-cell data indicated that LAG3 expression appeared to be complementary pattern to other immune checkpoints, implying multiple mechanisms of T cell exhaustion. Importantly, clinical data analysis demonstrated that elevated LAG3 expression is an independent poor prognostic factor for patient survival. These findings suggest that LAG3 may play a crucial role in regulating the immune microenvironment in gliomas and contribute to T cell exhaustion, alongside other immune checkpoints such as the PD-L1/PD-1 pathway. As such, LAG3 represents a potential therapeutic target for glioma immunotherapy.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma

  • Zheng Wang,
  • Haitao Fu,
  • Yuwei Li,
  • Zewei Liu,
  • Wenhua Fan,
  • Yuqing Liu,
  • Chuanbao Zhang,
  • Jingshan Liang,
  • Zhong Zhang,
  • Liyun Zhong,
  • Wei Yan

摘要

Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint expressed on the surface of T cells. We conducted a comprehensive molecular characterization and clinical analysis of LAG3 expression in gliomas. Across the CGGA and TCGA glioma datasets, we observed that LAG3 expression increased with higher glioma grade. Further investigation into the molecular subtypes revealed that LAG3 exhibited the highest expression in the Mesenchymal subtype, similar to other immune checkpoints. CIBERSORT analysis showed a significant positive correlation between LAG3 expression and macrophages, suggesting LAG3’s involvement in shaping the immune microenvironment. Single-cell data indicated that LAG3 expression appeared to be complementary pattern to other immune checkpoints, implying multiple mechanisms of T cell exhaustion. Importantly, clinical data analysis demonstrated that elevated LAG3 expression is an independent poor prognostic factor for patient survival. These findings suggest that LAG3 may play a crucial role in regulating the immune microenvironment in gliomas and contribute to T cell exhaustion, alongside other immune checkpoints such as the PD-L1/PD-1 pathway. As such, LAG3 represents a potential therapeutic target for glioma immunotherapy.